BioXcel Therapeutics, Inc. (BTAI) financial statements and ratios from SEC XBRL: revenue $642000.00 (TTM), net margin -10887.4%, revenue growth -71.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $642000.00 |
| Net Margin | -10887.4% |
| Revenue Growth (YoY) | -71.7% |
| EPS Growth (YoY) | -75.6% |
| FCF Growth (YoY) | -20.0% |
| Price / Sales | 36.63 |
| FCF Yield | -335.0% |
| Altman Z-Score | -26.29 (distress) |
| Piotroski F-Score | 3/9 |
| Sector P/E (Healthcare) | 21.7 |
BTAI overview · BTAI earnings · BTAI KPIs · BTAI investor relations · BTAI ownership · BTAI peers · BTAI filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.